Latest Nektar Therapeutics (NKTR) Headlines Nek
Post# of 68
Posted On: 03/13/2014 11:39:43 AM
Latest Nektar Therapeutics (NKTR) Headlines
Nektar Therapeutics Has Returned 12.9% Since SmarTrend Recommendation (NKTR)
Comtex SmarTrend(R) - Wed Mar 12, 5:19PM CDT
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on November 22nd, 2013 at $11.83. In approximately 4 months, Nektar Therapeutics has returned 12.93% as of today's recent price of $13.36.
Patient Support Programs, Financial Results, and Stock Price Movements - Analyst Notes on Gilead, Forest Laboratories, Thermo Fisher Scientific, HCA Holdings, and Nektar
PR Newswire - Thu Mar 06, 7:25AM CST
Editor Note: For more information about this release, please scroll to bottom.
Uptrend Call Working As Nektar Therapeutics Stock Rises 25.0% (NKTR)
Comtex SmarTrend(R) - Wed Mar 05, 11:11AM CST
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on November 22nd, 2013 at $11.83. In approximately 3 months, Nektar Therapeutics has returned 25.02% as of today's recent price of $14.79.
Nektar Therapeutics (NKTR) Jumps: Stock Up 10.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 8:39AM CST
Nektar Therapeutics was a big mover last session, as its shares rose nearly 11% on the day.
Wider-than-Expected Loss at Nektar, Guidance Disappoints - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 10:10AM CST
Nektar reported a loss of 41 cents per share in the fourth quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 16 cents.
Today's Biggest Stories in Biotech: Galectin Therapeutics Inc, Merrimack Pharmaceuticals and Nektar
George Budwell, The Motley Fool - Motley Fool - Thu Feb 27, 8:27AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
Downgrade Alert for Nektar Therapeutics (NKTR)
Comtex SmarTrend(R) - Thu Feb 27, 7:02AM CST
Nektar Therapeutics (NASDAQ:NKTR) was downgraded from Buy to Neutral at MKM Partners today. The stock closed yesterday at $13.70 on volume of 919,000 shares, below average daily volume of 1.2 million. Nektar Therapeutics (Nektar) is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar's research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.
Nektar Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results
PR Newswire - Wed Feb 26, 3:15PM CST
Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2013.
Nektar Therapeutics Up 13.5% Since SmarTrend Uptrend Call (NKTR)
Comtex SmarTrend(R) - Wed Feb 26, 10:06AM CST
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on November 22nd, 2013 at $11.83. In approximately 3 months, Nektar Therapeutics has returned 13.48% as of today's recent price of $13.43.
3 Under-the-Radar Biotech Stocks You Need to Watch in 2014
Dan Carroll, The Motley Fool - Motley Fool - Sun Feb 23, 3:53PM CST
No industry embraces the boom-or-bust potential of the stock market like the biotech industry. Under-the-radar stocks can produce huge returns for investors from successful drug approvals, milestone achievements, and other events. But which stocks...
Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2013 on Wednesday, February 26, 2014, After Close of U.S.-Based Financial Markets
PR Newswire - Wed Feb 19, 3:15PM CST
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2013 on Wednesday, February 26, 2014, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).
Uptrend Call Working As Nektar Therapeutics Stock Rises 16.2% (NKTR)
Comtex SmarTrend(R) - Wed Feb 19, 9:22AM CST
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on November 22nd, 2013 at $11.83. In approximately 3 months, Nektar Therapeutics has returned 16.23% as of today's recent price of $13.75.
European Data Centre Services Market
PR Newswire - Thu Feb 13, 4:53AM CST
Reportlinker.com announces that a new market research report is available in its catalogue:
Nektar Therapeutics Shares Up 12.8% Since SmarTrend's Buy Recommendation (NKTR)
Comtex SmarTrend(R) - Tue Feb 11, 9:24AM CST
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on November 22nd, 2013 at $11.83. In approximately 3 months, Nektar Therapeutics has returned 12.85% as of today's recent price of $13.35.
Concise Analysis of the North American Drug Delivery Technologies Market - Forecasts To 2017
M2 - Fri Feb 07, 4:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/qtbrf5/north_american) has announced the addition of the "Concise Analysis of the North American Drug Delivery Technologies Market - Forecasts To 2017" report to their offering. "Concise Analysis of the North American Drug Delivery Technologies Market - Forecasts To 2017", covers the market for technologies used for development of products, formulations, and devices used in drug delivery. The overall market is segmented based on the oral, pulmonary, trandermal, injectable, ocular, nasal, topical, implantable, and transmucosal routes of administration used by these technologies. Oral drug delivery technologies accounted for the largest share - 38% - of the North American market in 2012, under which controlled release and orodispersible tablet technologies and other technologies such as effervescent tablets and chewable tablets are covered. Pulmonary segment covers metered dose inhalers, dry-powder inhalers and nebulizers; this segment is growing at the highest CAGR of 11.8%. The transdermal technology market is divided into two types, namely, passive drug delivery and active drug delivery. Passive delivery is further categorized into reservoir system and matrix system, while active delivery is further categorized into iontophoresis, microporation and other technologies such as electroporation, sonophoresis and dermal ablation. Injectable technology market is classified as conventional injection, self injection, and other injection devices. Conventional devices include fillable syringes and prefilled syringes, whereas self injection devices include needle free injectors, auto-injectors, and pen injectors. Ocular drug delivery technologies market is divided into eye drops, ophthalmic ointments, gels and other formulations like ocular inserts and punctal plugs. Based on the type of formulation, nasal drug delivery technologies market is categorized into nasal drops, sprays, and inhalers. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 North America Drug Delivery Market, By Technology 5 Geographic Analysis 6 Competitive Landscape 7 Company Profiles Companies Mentioned: - Aptalis Pharma, Inc - Baxter International, Inc - Becton, Dickinson And Company - Catalent Pharma Solutions - Cima Labs - Endo Health Solutions, Inc - Johnson & Johnson, Inc - M Company - Nektar Therapeutics, Inc - Optinose As - Psivida Corporation - The Dow Chemical Company - Valeant Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/qt...h_american
Can Nektar Therapeutics Beat Pfizer Inc.?
Cory Renauer, The Motley Fool - Motley Fool - Tue Feb 04, 9:55AM CST
The development of effective medications for the management of chronic pain has been difficult for many pharma companies. Pfizer and Pain Therapeutics have gotten close with tamper resistant versions of Oxycodone. Nektar Therapeutics ,...
Competitor Analysis: Immunocytokines - 2014 Report
M2 - Mon Jan 27, 2:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/dgxmg2/competitor) has announced the addition of the "Competitor Analysis: Immunocytokines" report to their offering. The development of recombinant cytokines, or mainly antibody-cytokine fusion proteins, has been characterized by many drawbacks from dose-limiting toxicities. Over several years, development of new cytokines has stagnated, but recent R&D work with engineering of the cytokine payloads promises new molecular entities with better tolerability and safety. The present Competitive Intelligence report about Immunocytokines provides a competitor evaluation in the field of recombinant fusion proteins of a targeting moiety and a human cytokine as of January 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of recombinant immunocytokines with first and second generation cytokine payloads. In addition, the report lists company-specific R&D pipelines of Immunocytokines. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered: - Immunocytokines with TNF as Payload - Immunocytokines with First-Generation Interleukin-2 as Payload - Immunocytokines with Second-Generation Interleukin-2 as Payload - Immunocytokines with Interleukin-10 as Payload - Immunocytokines with Interleukin-12 as Payload - Immunocytokines with Interleukin-15 as Payload - Immunocytokines with Interferon as Payload - Corporate Immunocytokine R&D Pipelines Companies Mentioned - Alkermes - Alopexx Oncology - Altor Biosciences - Apeiron Biologics - AstraZeneca - Atlab Pharma - CytImmune - Cytune Pharma - ImmunGene - Immunomedics - Merck Serono - MolMed - Nektar Therapeutics - Paladin Labs - Pfizer - Philogen (Philochem) - Roche - Targa Therapeutics - Teva Pharmacuticcals - Valor Biotherapeutics For more information visit http://www.researchandmarkets.com/research/dgxmg2/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Nektar Therapeutics (NKTR) Looks Good: Stock Up 6.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 24, 7:44AM CST
Nektar Therapeutics was a big mover last session, as the company saw its shares rise nearly 7% on the day.
Nektar Therapeutics Has Returned 12.9% Since SmarTrend Recommendation (NKTR)
Comtex SmarTrend(R) - Wed Mar 12, 5:19PM CDT
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on November 22nd, 2013 at $11.83. In approximately 4 months, Nektar Therapeutics has returned 12.93% as of today's recent price of $13.36.
Patient Support Programs, Financial Results, and Stock Price Movements - Analyst Notes on Gilead, Forest Laboratories, Thermo Fisher Scientific, HCA Holdings, and Nektar
PR Newswire - Thu Mar 06, 7:25AM CST
Editor Note: For more information about this release, please scroll to bottom.
Uptrend Call Working As Nektar Therapeutics Stock Rises 25.0% (NKTR)
Comtex SmarTrend(R) - Wed Mar 05, 11:11AM CST
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on November 22nd, 2013 at $11.83. In approximately 3 months, Nektar Therapeutics has returned 25.02% as of today's recent price of $14.79.
Nektar Therapeutics (NKTR) Jumps: Stock Up 10.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 8:39AM CST
Nektar Therapeutics was a big mover last session, as its shares rose nearly 11% on the day.
Wider-than-Expected Loss at Nektar, Guidance Disappoints - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 10:10AM CST
Nektar reported a loss of 41 cents per share in the fourth quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 16 cents.
Today's Biggest Stories in Biotech: Galectin Therapeutics Inc, Merrimack Pharmaceuticals and Nektar
George Budwell, The Motley Fool - Motley Fool - Thu Feb 27, 8:27AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
Downgrade Alert for Nektar Therapeutics (NKTR)
Comtex SmarTrend(R) - Thu Feb 27, 7:02AM CST
Nektar Therapeutics (NASDAQ:NKTR) was downgraded from Buy to Neutral at MKM Partners today. The stock closed yesterday at $13.70 on volume of 919,000 shares, below average daily volume of 1.2 million. Nektar Therapeutics (Nektar) is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar's research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.
Nektar Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results
PR Newswire - Wed Feb 26, 3:15PM CST
Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2013.
Nektar Therapeutics Up 13.5% Since SmarTrend Uptrend Call (NKTR)
Comtex SmarTrend(R) - Wed Feb 26, 10:06AM CST
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on November 22nd, 2013 at $11.83. In approximately 3 months, Nektar Therapeutics has returned 13.48% as of today's recent price of $13.43.
3 Under-the-Radar Biotech Stocks You Need to Watch in 2014
Dan Carroll, The Motley Fool - Motley Fool - Sun Feb 23, 3:53PM CST
No industry embraces the boom-or-bust potential of the stock market like the biotech industry. Under-the-radar stocks can produce huge returns for investors from successful drug approvals, milestone achievements, and other events. But which stocks...
Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2013 on Wednesday, February 26, 2014, After Close of U.S.-Based Financial Markets
PR Newswire - Wed Feb 19, 3:15PM CST
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2013 on Wednesday, February 26, 2014, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).
Uptrend Call Working As Nektar Therapeutics Stock Rises 16.2% (NKTR)
Comtex SmarTrend(R) - Wed Feb 19, 9:22AM CST
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on November 22nd, 2013 at $11.83. In approximately 3 months, Nektar Therapeutics has returned 16.23% as of today's recent price of $13.75.
European Data Centre Services Market
PR Newswire - Thu Feb 13, 4:53AM CST
Reportlinker.com announces that a new market research report is available in its catalogue:
Nektar Therapeutics Shares Up 12.8% Since SmarTrend's Buy Recommendation (NKTR)
Comtex SmarTrend(R) - Tue Feb 11, 9:24AM CST
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on November 22nd, 2013 at $11.83. In approximately 3 months, Nektar Therapeutics has returned 12.85% as of today's recent price of $13.35.
Concise Analysis of the North American Drug Delivery Technologies Market - Forecasts To 2017
M2 - Fri Feb 07, 4:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/qtbrf5/north_american) has announced the addition of the "Concise Analysis of the North American Drug Delivery Technologies Market - Forecasts To 2017" report to their offering. "Concise Analysis of the North American Drug Delivery Technologies Market - Forecasts To 2017", covers the market for technologies used for development of products, formulations, and devices used in drug delivery. The overall market is segmented based on the oral, pulmonary, trandermal, injectable, ocular, nasal, topical, implantable, and transmucosal routes of administration used by these technologies. Oral drug delivery technologies accounted for the largest share - 38% - of the North American market in 2012, under which controlled release and orodispersible tablet technologies and other technologies such as effervescent tablets and chewable tablets are covered. Pulmonary segment covers metered dose inhalers, dry-powder inhalers and nebulizers; this segment is growing at the highest CAGR of 11.8%. The transdermal technology market is divided into two types, namely, passive drug delivery and active drug delivery. Passive delivery is further categorized into reservoir system and matrix system, while active delivery is further categorized into iontophoresis, microporation and other technologies such as electroporation, sonophoresis and dermal ablation. Injectable technology market is classified as conventional injection, self injection, and other injection devices. Conventional devices include fillable syringes and prefilled syringes, whereas self injection devices include needle free injectors, auto-injectors, and pen injectors. Ocular drug delivery technologies market is divided into eye drops, ophthalmic ointments, gels and other formulations like ocular inserts and punctal plugs. Based on the type of formulation, nasal drug delivery technologies market is categorized into nasal drops, sprays, and inhalers. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 North America Drug Delivery Market, By Technology 5 Geographic Analysis 6 Competitive Landscape 7 Company Profiles Companies Mentioned: - Aptalis Pharma, Inc - Baxter International, Inc - Becton, Dickinson And Company - Catalent Pharma Solutions - Cima Labs - Endo Health Solutions, Inc - Johnson & Johnson, Inc - M Company - Nektar Therapeutics, Inc - Optinose As - Psivida Corporation - The Dow Chemical Company - Valeant Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/qt...h_american
Can Nektar Therapeutics Beat Pfizer Inc.?
Cory Renauer, The Motley Fool - Motley Fool - Tue Feb 04, 9:55AM CST
The development of effective medications for the management of chronic pain has been difficult for many pharma companies. Pfizer and Pain Therapeutics have gotten close with tamper resistant versions of Oxycodone. Nektar Therapeutics ,...
Competitor Analysis: Immunocytokines - 2014 Report
M2 - Mon Jan 27, 2:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/dgxmg2/competitor) has announced the addition of the "Competitor Analysis: Immunocytokines" report to their offering. The development of recombinant cytokines, or mainly antibody-cytokine fusion proteins, has been characterized by many drawbacks from dose-limiting toxicities. Over several years, development of new cytokines has stagnated, but recent R&D work with engineering of the cytokine payloads promises new molecular entities with better tolerability and safety. The present Competitive Intelligence report about Immunocytokines provides a competitor evaluation in the field of recombinant fusion proteins of a targeting moiety and a human cytokine as of January 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of recombinant immunocytokines with first and second generation cytokine payloads. In addition, the report lists company-specific R&D pipelines of Immunocytokines. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered: - Immunocytokines with TNF as Payload - Immunocytokines with First-Generation Interleukin-2 as Payload - Immunocytokines with Second-Generation Interleukin-2 as Payload - Immunocytokines with Interleukin-10 as Payload - Immunocytokines with Interleukin-12 as Payload - Immunocytokines with Interleukin-15 as Payload - Immunocytokines with Interferon as Payload - Corporate Immunocytokine R&D Pipelines Companies Mentioned - Alkermes - Alopexx Oncology - Altor Biosciences - Apeiron Biologics - AstraZeneca - Atlab Pharma - CytImmune - Cytune Pharma - ImmunGene - Immunomedics - Merck Serono - MolMed - Nektar Therapeutics - Paladin Labs - Pfizer - Philogen (Philochem) - Roche - Targa Therapeutics - Teva Pharmacuticcals - Valor Biotherapeutics For more information visit http://www.researchandmarkets.com/research/dgxmg2/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Nektar Therapeutics (NKTR) Looks Good: Stock Up 6.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 24, 7:44AM CST
Nektar Therapeutics was a big mover last session, as the company saw its shares rise nearly 7% on the day.
(0)
(0)Nektar Therapeutics (NKTR) Stock Research Links
Scroll down for more posts ▼